Emergence of multidrug-resistant strain of Vibrio cholerae OI in Bangladesh and reversal of their susceptibility to tetracycline after two years

Journal of Health, Population and Nutrition

Volumn 25, Issue 2, 2007, Pages 241-243

  Faruque, Abu S G ^a   Alam, Khorshed ^a   Malek, Mohammad A ^a   Khan, Mohammed G Y ^a   Ahmed, Sabeena ^a   Saha, Debasish ^a   Khan, Wasif A ^a   Nair, Gopinath B ^a   Salam, Mohammed A ^a   Luby, Stephen P ^a   Sack, David A ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TETRACYCLINE;

BACTERIAL COUNT; BANGLADESH; CHOLERA; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LETTER; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; VIBRIO CHOLERAE;

ANTI-BACTERIAL AGENTS; BANGLADESH; CHOLERA; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TETRACYCLINE; VIBRIO CHOLERAE O1;

VIBRIO CHOLERAE;

EID: 35348950117     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004;363:223-33.
2. Greenough WB, 3rd, Gordon RS, Jr., Rosenberg IS, Davies BI, Benenson AS. Tetracycline in the treatment of cholera. Lancet 1964;41:355-7.
3. World Health Organization. Guidelines for cholera control. Geneva: World Health Organization, 1993. 46 p.
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disc susceptibility tests. 4th ed. Approved standard M2-A5. Villanova, PA: National Committee for Clinical Laboratory Standards, 1990. 65 p.
5. Koplan JP, Hughes JM, Cohen ML, Samba EM, Kabore AB, Bopp CA et al. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta, GA: Centers for Disease Control and Prevention, 1999. 71 p.
6. Khan WA, Bennish ML, Seas C, Khan EH, Ronan A, Dhar U et al. Randomized controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139. Lancet 1996;348:296-300.
7. Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005; 366:1085-93.
8. Salam MA, Saha D, Karim MM, Khan WA, Ahmed S. The quest for new drug in the treatment of cholera in adults: evaluation of efficacy of rifaximin in a randomized, controlled clinical trial (abstract). In: 40th Joint Meeting of the US-Japan Cholera and Other Bacterial Enteric Infections Panel, Boston, USA (30 November-2 December 2005). Boston: Organizer, 2005:218.
9. Siddique AK, Zaman K, Majumder Y, Islam Q, Bashir I, Mutsuddy P et al. Simultaneous outbreaks of contrasting drug resistant classic and El Tor Vibrio cholerae O1 in Bangladesh. Lancet 1989;2:350.
10. Urassa WK, Mhando YB, Mhalu FS, Mjonga SJ. Antimicrobial susceptibility pattern of Vibrio cholerae O1 strains during two cholera outbreaks in Dar es Salaam, Tanzania. East Afr Med J 2000;77:350-3.
11. Zachariah R, Harries AD, Arendt V, Nchingula D, Chimtulo F, Courteille O et al. Characteristics of a cholera outbreak, patterns of Vibrio cholerae and antibiotic susceptibility testing in rural Malawi. Trans R Soc Trop Med Hyg 2002;96:39-40.
12. Glass RI, Huq I, Alim ARMA, Yunus M. Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh. J Infect Dis 980;142;939-42.
13. Glass RI, Huq MI, Lee V, Threlfall EJ, Khan MR, Alim ARMA et al. Plasmid-borne multiple drug resistance in Vibrio cholerae serogroup O1, biotype El Tor: evidence for a point-source outbreak in Bangladesh. J Infect Dis 1983;147:204-9.